WaelAHarbMD

Oncology • Lafayette, IN

Founder of Horizon Oncology Center

Join to view full profile

Dr. Harb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Harb's full profile

Already have an account?

Office
1345 Unity Pl
Ste.365
Lafayette, IN 47905
Phone+1 765-446-5165

Fax+1 765-838-0972
Is this information wrong?

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
Damascus University Faculty of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 2021 - 2025
MI State Medical License 2018 - 2023
IN State Medical License 1996 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors Start of enrollment: 2011 Oct 01
Completed
Phase 1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
Completed
Phase 1
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 Nov 01
Completed
Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Start of enrollment: 2014 Mar 05
Completed
Phase 1
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
Completed
Phase 1
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Start of enrollment: 2014 Jul 16
Active, not recruiting
Phase 1, Phase 2
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15
Completed
Phase 1, Phase 2
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Start of enrollment: 2017 Nov 28
Active, not recruiting
Phase 1
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Colak, G., Fusco, A., Mangan, J., Stein, E., Fathi, A., Harb, W.> ;Leukemia & Lymphoma. 2024 Apr 1
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Bullock, A., Watnick, R., Vincent, M., Chen, J., Wang, S., Pestana, H., Chao, J., Mahoney, J., Cieslewicz, M., Watnick, J., Mahalingam, D., Harb, W., Patnaik, A.> ;Communications Medicine. 2024 Jan 13
7 citations
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I ...
Wael Harb, Daruka Mahadevan, Hani Babiker, Jordan Berlin, Tom Lillie, David Krige, Jo Carter, Chris Cox, Minesh Patel, Lola Parfitt, Mark Powell, Lee Rosen, Fakih, M.> ;Journal for Immunotherapy of Cancer. 2023 Apr 1
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jason R. Westin, Michael B. Maris, Caron A. Jacobson, Prapti A. Patel, Nehal Lakhani, Wael A. Harb, Dipti Patel-Donnelly, Kelly McCaul, Carolina Escobar, Barbara Klenc...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jul 25
3 citations
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies
Wael A. Harb, Nehal Lakhani, Richard A. Messmann, Barbara Klencke, Ayad Al-Katib> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jul 23
30 citations
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Wael A. Harb, Cody J. Peer, Qiong Hua, Siying Xu, Haolan Lu, Ni Lu, Yue He, Ting Xu, Ruiping Dong, John Gong, David T.L. Liu> ;The Oncologist. 2021 Sep 1
12 citations
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.
Alexander I. Spira, Aaron R. Hansen, Wael A. Harb, Kelly K. Curtis, Erina Koga-Yamakawa, Makoto Origuchi, Zhonggai Li, Bella Ertik, Walid L. Shaib> ;Targeted Oncology. 2021 May 3
53 citations
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards, Wael A. Harb, Cynthia Osborne, Robert Wesolowski, Meghan Sri Karuturi, Paul Conkling...> ;Journal of Clinical Oncology. 2021 Jan 29
78 citations
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer ...
Greg Andrew Durm, Salma K. Jabbour, Sandra Althouse, Ziyue Liu, Ahad Ali Sadiq, Robin Zon, Shadia I. Jalal, Goetz H. Kloecker, Michael J. Williamson, Karen L. Reckamp,...> ;Cancer. 2020 Oct 1
46 citations
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Steven Falchook, Seth Rosen, Patricia LoRusso, Justin M. Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica M. Mita, Ryan D. Cassa...> ;Clinical Cancer Research. 2020 Mar 15
28 citations
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia V. Sequist, Jhanelle E. Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele, Manuel Modiano, David M. Jackman, Maria Q. Baggstrom, Akin Atmaca, Enriqueta F...> ;The Oncologist. 2019 Aug 1
81 citations
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, Wael Harb, Hagop M. Kantarjian, James N. L...> ;The Lancet. Haematology. 2019 Apr 1
31 citations
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Jordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, Wael Harb, Analia Azaro, Yu Han, C. Wilke, Valerie Donnet, Dalila Sellami, Thaddeus Beck> ;Oncotarget. 2018 Aug 3
15 citations
Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders
Rachel N. Grisham, Kathleen N. Moore, Michael S. Gordon, Wael A. Harb, Gwendolyn R. Cody, Darragh Halpenny, Vicky Makker, Carol Aghajanian> ;Clinical Cancer Research. 2018 Jan 1
13 citations
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael A. Harb, Hui Yang, Dawn E. Pinchasik, Amy S. Kimball, James R. Berenson> ;Clinical Lymphoma, Myeloma & Leukemia. 2017 Jul 1
12 citations
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
James R. Berenson, Robert F. Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger M. Lyons, Wael A. Harb, Hesham Mohamed, Ali Nourbakhsh, Robert M. Rifkin> ;American Journal of Hematology. 2017 May 1
70 citations
Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger...> ;Haematologica. 2016 Jul 1
84 citations
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael A. Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, Morton Coleman, Robert A. Moss,...> ;Blood. 2016 Jun 30
58 citations
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael A. Harb, Leo I. Gordon, Robert M. Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying L...> ;Clinical Cancer Research. 2016 Mar 1
15 citations
Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options
Wael A. Harb> ;Cancer Management and Research. 2015 Jan 21
93 citations
Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Cristina Saura, José A. García-Sáenz, Binghe Xu, Wael Harb, Rebecca L. Moroose, Timothy Pluard, Javier Cortes, Corinne Kiger, C. Germa, Kongming Wang, Miguel Martin, J...> ;Journal of Clinical Oncology. 2014 Nov 10
33 citations
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
James R. Berenson, James Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, Kenneth Dressler, Hassan H. Ghazal, Saad Jamshed, Edwin Kingsley, Wael A. Harb, Stephen J...> ;Annals of Hematology. 2014 Jan 1
27 citations
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinu...
R Wendel Naumann, Robert L Coleman, Robert A Burger, Edward A Sausville, Elzbieta Kutarska, Sharad A Ghamande, Nashat Y Gabrail, Stephen E Depasquale, Elzbieta Nowara,...> ;Journal of Clinical Oncology. 2013 Dec 10
363 citations
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobagyi, Mario Campone, Barbara Pistilli, Ma...> ;Advances in Therapy. 2013 Oct 25
146 citations
Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay
Wael A. Harb, Andrea Fan, Tony Tran, Daniel C. Danila, David N. Keys, Michael J. Schwartz, Cristian Ionescu-Zanetti> ;Translational Oncology. 2013 Oct 1
Join now to see all

Press Mentions

Lung Cancer: Immunotherapy Combined with Chemotherapy May Improve Quality of Life in Hard-to-Treat CasesMay 24th, 2023
Taking Vitamin D Daily May Reduce Cancer Mortality by 12%May 17th, 2023
Cannabis Relieves Pain, Improves Sleep, and Lifts Brain Fog in Cancer PatientsMay 5th, 2023
Join now to see all